A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Clinical trial NCT04296370 · UNKNOWN
Trial details
- NCT number
- NCT04296370
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-13
- Primary completion
- 2022-06-30
- Enrollment
- 474
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.